Skip to main
MDXH

MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth SA (MDXH) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MDxHealth is a molecular diagnostics lab with a strong focus on prostate testing, which currently generates the majority of its revenue from the United States. Its innovative tests, such as the SelectMDx and ConfirmMDx, offer highly personalized and actionable information to physicians and have the potential to significantly reduce the number of unnecessary biopsies and associated risks. With a solid track record of successful acquisitions and new partnerships, MDxHealth is well-positioned for continued growth and is expected to generate significant cost savings for the U.S. healthcare system.

Bears say

MDxHealth is facing significant challenges in the wake of a Q1 earnings miss and a surprise material guide down for 2026. The company is discontinuing its UTI test, which caught investors off guard, and is facing a reimbursement issue that could result in a recoupment payment of $10M from Medicare. Additionally, there is uncertainty around the company's ability to access new debt and its current debt is fully borrowed, making it imperative for MDxHealth to control costs and achieve positive free cash flow in 2027. Hence, the outlook for the stock is negative, with a lowered price target of $1.50.

MDxHealth SA (MDXH) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MDxHealth SA (MDXH) Forecast

Analysts have given MDxHealth SA (MDXH) a Strong Buy based on their latest research and market trends.

According to 3 analysts, MDxHealth SA (MDXH) has a Strong Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MDxHealth SA (MDXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.